Advanced search
Publication Cover
Cell Cycle Volume 17, 2018 - Issue 4
Submit an article Journal homepage
2,526
Views
27
CrossRef citations to date
0
Altmetric
Reports

Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies

Varun V. PrabhuOncoceutics, Inc., Philadelphia, PACorrespondence[email protected]
View further author information
,
Mala K. TalekarThe Children's Hospital of Philadelphia, Philadelphia, PAView further author information
,
Amriti R. LullaFox Chase Cancer Center, Philadelphia, PAORCID Iconhttp://orcid.org/0000-0002-7085-5755View further author information
ORCID Icon,
C. Leah B. KlineFox Chase Cancer Center, Philadelphia, PAView further author information
,
Lanlan ZhouFox Chase Cancer Center, Philadelphia, PAORCID Iconhttp://orcid.org/0000-0001-9471-9099View further author information
ORCID Icon,
Junior HallThe Children's Hospital of Philadelphia, Philadelphia, PAView further author information
,
A. Pieter J. Van den HeuvelPenn State College of Medicine, Hershey, PAView further author information
,
David T. DickerFox Chase Cancer Center, Philadelphia, PAView further author information
,
Jawad BabarFox Chase Cancer Center, Philadelphia, PAORCID Iconhttp://orcid.org/0000-0001-8025-7444View further author information
ORCID Icon,
Stephan A. GruppThe Children's Hospital of Philadelphia, Philadelphia, PAView further author information
,
Mathew J. GarnettWellcome Trust Sanger Institute, Hinxton, UKView further author information
,
Ultan McDermottWellcome Trust Sanger Institute, Hinxton, UKView further author information
,
Cyril H. BenesMassachusetts General Hospital, Harvard Medical School, Boston, MAView further author information
,
Jeffrey J. PuPenn State College of Medicine, Hershey, PAView further author information
,
David F. ClaxtonPenn State College of Medicine, Hershey, PAView further author information
,
Nadia KhanFox Chase Cancer Center, Philadelphia, PAORCID Iconhttp://orcid.org/0000-0001-8259-4129View further author information
ORCID Icon,
Wolfgang OsterOncoceutics, Inc., Philadelphia, PAView further author information
,
Joshua E. AllenOncoceutics, Inc., Philadelphia, PAView further author information
&
Wafik S. El-DeiryOncoceutics, Inc., Philadelphia, PACorrespondence[email protected]
View further author information
 show all
Pages 468-478 | Received 15 Sep 2017, Accepted 02 Nov 2017, Published online: 19 Feb 2018

Citations (27)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Andrea Patriarca & Gianluca Gaidano. (2021) Investigational drugs for the treatment of diffuse large B-cell lymphoma. Expert Opinion on Investigational Drugs 30:1, pages 25-38.
Read now
Luca Bertamini, Francesca Bonello, Mario Boccadoro & Sara Bringhen. (2020) New drugs in early development for treating multiple myeloma: all that glitters is not gold. Expert Opinion on Investigational Drugs 29:9, pages 989-1004.
Read now
Holly Edwards & Yubin Ge. (2018) ONC201 shows promise in AML treatment. Cell Cycle 17:3, pages 277-277.
Read now

Articles from other publishers (24)

Adrian Schwarzer, Matheus Oliveira, Marc-Jens Kleppa, Scott D. Slattery, Andy Anantha, Alan Cooper, Mark Hannink, Axel Schambach, Anneke Dörrie, Alexey Kotlyarov, Matthias Gaestel, Todd Hembrough, Jedd Levine, Michael Luther, Michael Stocum, Linsey Stiles, David M. Weinstock, Marc Liesa & Matthew J. Kostura. (2023) Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1. Molecular Cancer Therapeutics 22:11, pages 1290-1303.
Crossref
Xia Jiang, Ye Lin, Mengting Zhao, Youhong Li, Peipei Ye, Renzhi Pei, Ying Lu & Lei Jiang. (2023) Platycodin D induces apoptotic cell death through PI3K/AKT and MAPK/ERK pathways and synergizes with venetoclax in acute myeloid leukemia. European Journal of Pharmacology 956, pages 175957.
Crossref
Rohan Wedam, Yoshimi Endo Greer, David J. Wisniewski, Sarah Weltz, Manjari Kundu, Donna Voeller & Stanley Lipkowitz. (2023) Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer. Cancers 15:7, pages 1936.
Crossref
Gus O. Nwosu, Jason A. Powell & Stuart M. Pitson. (2022) Targeting the integrated stress response in hematologic malignancies. Experimental Hematology & Oncology 11:1.
Crossref
Bruno Toson, Isadora S. Fortes, Rafael Roesler & Saulo F. Andrade. (2022) Targeting Akt/PKB in pediatric tumors: A review from preclinical to clinical trials. Pharmacological Research 183, pages 106403.
Crossref
Trang T.T. Nguyen, Enyuan Shang, Salveena Schiffgens, Consuelo Torrini, Chang Shu, Hasan Orhan Akman, Varun V. Prabhu, Joshua E. Allen, Mike-Andrew Westhoff, Georg Karpel-Massler & Markus D. Siegelin. (2022) Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma. Clinical Cancer Research 28:9, pages 1881-1895.
Crossref
Tamás Czuczi, József Murányi, Péter Bárány, István Móra, Adina Borbély, Miklós Csala & Antal Csámpai. (2022) Synthesis and Antiproliferative Activity of Novel Imipridone–Ferrocene Hybrids with Triazole and Alkyne Linkers. Pharmaceuticals 15:4, pages 468.
Crossref
Alessandro Allegra, Emanuela Sant’Antonio, Caterina Musolino & Roberta Ettari. (2022) New Insights into Neuropeptides Regulation of the Immune System and Hemopoiesis: Effects on Hematologic Malignancies. Current Medicinal Chemistry 29:14, pages 2412-2437.
Crossref
Yali Fan, Jiandong Wang, Ziwei Fang, Stuart R. Pierce, Lindsay West, Allison Staley, Katherine Tucker, Yajie Yin, Wenchuan Sun, Weimin Kong, Varun Prabhu, Joshua E. Allen, Chunxiao Zhou & Victoria L. Bae-Jump. (2022) Anti-Tumor and Anti-Invasive Effects of ONC201 on Ovarian Cancer Cells and a Transgenic Mouse Model of Serous Ovarian Cancer. Frontiers in Oncology 12.
Crossref
Yu-Hsuan Fu, Chi-Yang Tseng, Jeng-Wei Lu, Wen-Hui Lu, Pei-Qi Lan, Chien-Yuan Chen, Da-Liang Ou & Liang-In Lin. (2021) Deciphering the Role of Pyrvinium Pamoate in the Generation of Integrated Stress Response and Modulation of Mitochondrial Function in Myeloid Leukemia Cells through Transcriptome Analysis. Biomedicines 9:12, pages 1869.
Crossref
R. Benjamin Free, Caroline A. Cuoco, Bing Xie, Yoon Namkung, Varun V. Prabhu, Blair K.A. Willette, Marilyn M. Day, Marta Sanchez-Soto, J. Robert Lane, Stéphane A. Laporte, Lei Shi, Joshua E. Allen & David R. Sibley. (2021) Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the D 2 Dopamine Receptor . Molecular Pharmacology 100:4, pages 372-387.
Crossref
Angéla Takács, Zsófia Szász, Márton Kalabay, Péter Bárány, Antal Csámpai, Hargita Hegyesi, Orsolya Láng, Eszter Lajkó & László Kőhidai. (2021) The Synergistic Activity of Bortezomib and TIC10 against A2058 Melanoma Cells. Pharmaceuticals 14:8, pages 820.
Crossref
Ling He, Kruttika Bhat, Angeliki Ioannidis, Le Zhang, Nhan T. Nguyen, Joshua E. Allen, Phioanh Leia Nghiemphu, Timothy F. Cloughesy, Linda M. Liau, Harley I. Kornblum & Frank Pajonk. (2021) Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma. Radiotherapy and Oncology 161, pages 140-147.
Crossref
Yiqun Zhang, Lanlan Zhou, Howard Safran, Robyn Borsuk, Rishi Lulla, Nikos Tapinos, Attila A. Seyhan & Wafik S. El-Deiry. (2021) EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG. Neoplasia 23:8, pages 792-810.
Crossref
Ashraf Al Madhoun, Dania Haddad, Mustafa Al Tarrah, Sindhu Jacob, Waleed Al-Ali, Rasheeba Nizam, Lavina Miranda, Fatema Al-Rashed, Sardar Sindhu, Rasheed Ahmad, Milad S. Bitar & Fahd Al-Mulla. (2021) Microarray analysis reveals ONC201 mediated differential mechanisms of CHOP gene regulation in metastatic and nonmetastatic colorectal cancer cells. Scientific Reports 11:1.
Crossref
Narjis Fatima, Yandong Shen, Kyle Crassini, Edwin J. Iwanowicz, Henk Lang, Donald S. Karanewsky, Richard I. Christopherson, Stephen P. Mulligan & Oliver G. Best. (2021) The ClpP activator ONC‐212 (TR‐31) inhibits BCL2 and B‐cell receptor signaling in CLL. eJHaem 2:1, pages 81-93.
Crossref
Jenna L. Carter, Katie Hege, Jay Yang, Hasini A. Kalpage, Yongwei Su, Holly Edwards, Maik Hüttemann, Jeffrey W. Taub & Yubin Ge. (2020) Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduction and Targeted Therapy 5:1.
Crossref
Debasmita Mukherjee, Lena S. Bercz, Molly A. Torok & Thomas A. Mace. (2020) Regulation of cellular immunity by activating transcription factor 4. Immunology Letters 228, pages 24-34.
Crossref
Trang T. T. Nguyen, Yiru Zhang, Enyuan Shang, Chang Shu, Catarina M. Quinzii, Mike-Andrew Westhoff, Georg Karpel-Massler & Markus D. Siegelin. (2020) Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems. Cells 9:7, pages 1661.
Crossref
Yang Liu, Zhen Zhang, Fansheng Ran, Kaiwen Guo, Xin Chen & Guisen Zhao. (2020) Extensive investigation of benzylic N-containing substituents on the pyrrolopyrimidine skeleton as Akt inhibitors with potent anticancer activity. Bioorganic Chemistry 97, pages 103671.
Crossref
Isabel Arrillaga-Romany, Yazmin Odia, Varun V Prabhu, Rohinton S Tarapore, Krystal Merdinger, Martin Stogniew, Wolfgang Oster, Joshua E Allen, Minesh Mehta, Tracy T Batchelor & Patrick Y Wen. (2020) Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro-Oncology 22:1, pages 94-102.
Crossref
Zhe Cao, Qianjin Liao, Min Su, Kai Huang, Junfei Jin & Deliang Cao. (2019) AKT and ERK dual inhibitors: The way forward?. Cancer Letters 459, pages 30-40.
Crossref
Germana Castelli, Elvira Pelosi & Ugo Testa. (2019) Emerging Therapies for Acute Myelogenus Leukemia Patients Targeting Apoptosis and Mitochondrial Metabolism. Cancers 11:2, pages 260.
Crossref
Hanley N. Abramson. (2018) The Multiple Myeloma Drug Pipeline—2018: A Review of Small Molecules and Their Therapeutic Targets. Clinical Lymphoma Myeloma and Leukemia 18:9, pages 611-627.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.